Amarin Gets Outside Help in High Court Bid to Save Drug Patents

March 5, 2021, 9:12 PM

The Federal Circuit’s approach to evaluating patents will undermine incentives Congress created for developing innovative medications unless the U.S. Supreme Court steps in, a health policy organization told the high court in an amicus brief.

Amarin Pharma Inc. wants the Supreme Court to revive its six canceled patents on the heart treatment Vascepa, which weren’t set to expire until 2030. The drug is Amarin’s sole product and accounts for all of the company’s revenues.

Cancellation of the patents opens the door to generic copycats from drug makers Hikma Pharmaceuticals Plc and Dr. Reddy’s Laboratories Ltd., who brought the challenge....

To read the full article log in. To learn more about a subscription click here.